HK Stock Market Move | ABBISKO-B(02256) rose nearly 8% intraday; ABSK061 Phase II clinical study achieved positive preliminary efficacy results.

ABBISKO-B(02256) rose nearly 8% intraday. As of press time, it was up 7.05% at HK$8.88, with a turnover of HK$10.4256 million. On the news front, Abbisko announced that the Phase II clinical study of lavengratinib (ABSK061), a selective oral small molecule FGFR2/3 inhibitor developed by its subsidiary Abbisko Pharmaceuticals, for the treatment of pediatric achondroplasia achieved positive preliminary efficacy results. Zhongtai recently issued a research report adjusting Abbisko's earnings forecasts, mainly to adjust the pace of milestone revenue recognition related to pimicotinib licensing based on the company's revenue situation in the first half of 2026, without changing the core pipeline and the logic of BD value realization. The newly added multi-asset collaboration with Eli Lilly further demonstrates the advanced nature of the company's technology platform. As core assets continue to advance and subsequent milestones and collaboration value are gradually released, the company's medium- to long-term growth logic is clear, and the "Buy" rating is maintained.